Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ASM
|
|||
| Former ID |
DIB009090
|
|||
| Drug Name |
NPC-15199
|
|||
| Synonyms |
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; F-L-Leu; CHEMBL294989; PPARgamma Activator, Fmoc-Leu; 2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid; Fmoc-DL-leucine; N-alpha-Fmoc-L-leucine; NSC334290; ACMC-209iik; AC1L1HVH; n-[(9h-fluoren-9-ylmethoxy)carbonyl]leucin; ACMC-2099ky; AC1Q5SK7; 126727-03-5; 2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-methyl-pentanoic acid; (2S)-2-[(fluoren-9-ylmethoxy)carbonylamino]-4-methylpentanoic acid; GTPL2705; SCHEMBL1002861; CHEBI:91726; CTK8G6077; MolPort-003-700-319; HMS3266H19; SBB056939; IN1334; BDBM50034787; AKOS017268980
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Phase 2 | [1] | |
| Company |
Scios Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23NO4
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
|||
| InChI |
1S/C21H23NO4/c1-13(2)11-19(20(23)24)22-21(25)26-12-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h3-10,13,18-19H,11-12H2,1-2H3,(H,22,25)(H,23,24)/t19-/m0/s1
|
|||
| InChIKey |
CBPJQFCAFFNICX-IBGZPJMESA-N
|
|||
| CAS Number |
CAS 35661-60-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium release (Ca rele) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001904) | |||
| REF 2 | NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.